{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:44:59Z","timestamp":1792129499163,"version":"4.4.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1053\/j.seminhematol.2026.05.005","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T04:01:25Z","timestamp":1778817685000},"page":"110-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know"],"prefix":"10.1053","volume":"63","author":[{"given":"Orly","family":"Leiva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia C.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios P.","family":"Katsadouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1053\/j.seminhematol.2026.05.005_bib0001","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jaccao.2025.05.010","article-title":"Beyond thrombosis: pulmonary hypertension and heart failure in patients with myeloproliferative neoplasms: JACC: CardioOncology state-of-the-art review","volume":"7","author":"Leiva","year":"2025","journal-title":"JACC CardioOncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.005_bib0002","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaccao.2022.04.002","article-title":"Cardiovascular disease in myeloproliferative neoplasms: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Leiva","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.05.005_bib0003","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jacbts.2019.05.013","article-title":"JAK2 (V617F)-mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure","volume":"4","author":"Sano","year":"2019","journal-title":"JACC Basic Transl Sci"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.05.005_bib0004","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3390\/cells8080854","article-title":"Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation","volume":"8","author":"Perner","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.05.005_bib0005","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12885-019-5387-9","article-title":"A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms","volume":"19","author":"Rungjirajittranon","year":"2019","journal-title":"BMC Cancer"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.05.005_bib0006","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.05.005_bib0007","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.05.005_bib0008","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/jama.2022.0358","article-title":"Diagnosis and treatment of acute coronary syndromes: a review","volume":"327","author":"Bhatt","year":"2022","journal-title":"JAMA"},{"key":"10.1053\/j.seminhematol.2026.05.005_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1369701","article-title":"Prediction of acute coronary syndrome in patients with myeloproliferative neoplasms","volume":"11","author":"Huang","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.005_bib0010","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.hoc.2020.11.006","article-title":"Thrombotic, vascular, and bleeding complications of the myeloproliferative neoplasms","volume":"35","author":"Schafer","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.005_bib0011","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.canep.2015.01.014","article-title":"Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm","volume":"39","author":"Wu","year":"2015","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.005_bib0012","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3390\/hematolrep15020040","article-title":"Risk factors for death or cardiovascular events after acute coronary syndrome in patients with myeloproliferative neoplasms","volume":"15","author":"Leiva","year":"2023","journal-title":"Hematol Rep"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.05.005_bib0013","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaccao.2023.03.014","article-title":"Outcomes of patients with myeloproliferative neoplasms admitted with myocardial infarction: insights from national inpatient sample","volume":"5","author":"Leiva","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1053\/j.seminhematol.2026.05.005_bib0014","article-title":"Readmission outcomes after acute coronary syndrome among patients with myeloproliferative neoplasms","volume":"401","author":"Leiva","year":"2024","journal-title":"Atherosclerosis"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.05.005_bib0015","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.05.005_bib0016","first-page":"1535","article-title":"Trends and outcomes following percutaneous coronary intervention in patients with myeloproliferative neoplasms: insights from national database","volume":"105","author":"Ang","year":"2025","journal-title":"Catheter Cardiovasc Interv"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.005_bib0017","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/ejh.13721","article-title":"Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): a retrospective single-center study of 829 MPN patients","volume":"108","author":"Wille","year":"2022","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.05.005_bib0018","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40256-022-00541-w","article-title":"Abbreviated versus standard duration of DAPT after PCI: a systematic review and network meta-analysis","volume":"22","author":"Park","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.05.005_bib0019","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/eurheartj\/ehac706","article-title":"Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials","volume":"44","author":"Costa","year":"2023","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.05.005_bib0020","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2025.05.010","article-title":"Recurrent events analysis of MASTER DAPT: total ischemic and bleeding events after abbreviated vs prolonged DAPT in HBR patients","volume":"86","author":"Bongiovanni","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1053\/j.seminhematol.2026.05.005_bib0021","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/j.jacc.2007.11.077","article-title":"Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease","volume":"51","author":"Welten","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.05.005_bib0022","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jvs.2014.03.290","article-title":"Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population","volume":"60","author":"Nehler","year":"2014","journal-title":"J Vasc Surg"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.05.005_bib0023","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1002\/ajh.23874","article-title":"Occurrence of the JAK2 V617F mutation in patients with peripheral arterial disease","volume":"90","author":"Muendlein","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2026.05.005_bib0024","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2023.04.021","article-title":"Atrial fibrillation and peripheral arterial disease define MPN patients with very high risk of thrombosis","volume":"226","author":"Herbreteau","year":"2023","journal-title":"Thromb Res"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.05.005_bib0025","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s11239-025-03088-0","article-title":"Outcomes of patients with myeloproliferative neoplasms and critical limb ischemia: insights from the National readmissions database","volume":"58","author":"Leiva","year":"2025","journal-title":"J Thromb Thrombolysis"},{"issue":"24","key":"10.1053\/j.seminhematol.2026.05.005_bib0026","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"issue":"38","key":"10.1053\/j.seminhematol.2026.05.005_bib0027","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.05.005_bib0028","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.echo.2025.01.006","article-title":"Guidelines for the echocardiographic assessment of the right heart in adults and special considerations in pulmonary hypertension: recommendations from the American Society of Echocardiography","volume":"38","author":"Mukherjee","year":"2025","journal-title":"J Am Soc Echocardiogr"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.05.005_bib0029","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/rccm.202210-1941OC","article-title":"Clinical phenotype and outcomes of pulmonary hypertension associated with myeloproliferative neoplasms: a population-based study","volume":"208","author":"Montani","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl_3","key":"10.1053\/j.seminhematol.2026.05.005_bib0030","doi-asserted-by":"crossref","DOI":"10.1161\/circ.152.suppl_3.4372348","article-title":"Abstract 4372348: characterization and prognostic implications of pulmonary hypertension on right heart catheterization among patients with myeloproliferative neoplasms","volume":"152","author":"Leiva","year":"2025","journal-title":"Circulation"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.05.005_bib0031","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.echo.2019.07.010","article-title":"Incremental utility of right ventricular dysfunction in patients with myeloproliferative neoplasm-associated pulmonary hypertension","volume":"32","author":"Kim","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.05.005_bib0032","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12185-022-03454-1","article-title":"Pulmonary hypertension is associated with poor cardiovascular and hematologic outcomes in patients with myeloproliferative neoplasms and cardiovascular disease","volume":"117","author":"Leiva","year":"2023","journal-title":"Int J Hematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.05.005_bib0033","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.124.017986","article-title":"Impact of echocardiographic probability of pulmonary hypertension on prognosis and outcomes among patients with myeloproliferative neoplasms","volume":"18","author":"Leiva","year":"2025","journal-title":"Circ Cardiovasc Imaging"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.05.005_bib0034","first-page":"2388","article-title":"Characterization and prognostic implication of pulmonary hypertension among patients with myeloproliferative neoplasms","volume":"110","author":"Leiva","year":"2025","journal-title":"Haematologica"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.05.005_bib0035","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"16","key":"10.1053\/j.seminhematol.2026.05.005_bib0036","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.3390\/diagnostics15162042","article-title":"Intersecting pathways: the impact of Philadelphia-negative chronic myeloproliferative neoplasms on the pathogenesis and progression of heart failure with preserved ejection fraction","volume":"15","author":"Mih\u0103il\u0103","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"10.1053\/j.seminhematol.2026.05.005_bib0037","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1182\/blood-2024-207586","article-title":"Incidence, risk factors, and prognostic implications of heart failure hospitalizations among patients with myeloproliferative neoplasms","volume":"144","author":"Leiva","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.05.005_bib0038","article-title":"In-hospital and readmission outcomes of patients with myeloproliferative neoplasms and heart failure: insights from the National Readmissions Database","volume":"49","author":"Leiva","year":"2023","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.05.005_bib0039","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/ijms23063206","article-title":"Thromboinflammation in myeloproliferative neoplasms (MPN)-a puzzle still to be solved","volume":"23","author":"Bhuria","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.05.005_bib0040","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"issue":"21","key":"10.1053\/j.seminhematol.2026.05.005_bib0041","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","article-title":"Comparative effectiveness of aspirin dosing in cardiovascular disease","volume":"384","author":"Jones","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.05.005_bib0042","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/ajh.27002","article-title":"Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.05.005_bib0043","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.27216","article-title":"Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Tefferi","year":"2024","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.05.005_bib0044","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.3109\/10428194.2013.790022","article-title":"Antileukemic properties of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors","volume":"54","author":"van Besien","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.005_bib0045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjh.12103","article-title":"JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth","volume":"160","author":"Griner","year":"2013","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.05.005_bib0046","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1182\/bloodadvances.2026019625","article-title":"Prime time for the use of statins in MPNs: from comorbidity drugs to disease-modifying partners","volume":"10","author":"Hasselbalch","year":"2026","journal-title":"Blood Adv"},{"issue":"14","key":"10.1053\/j.seminhematol.2026.05.005_bib0047","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/bloodadvances.2023009784","article-title":"Use of statins and risk of myeloproliferative neoplasms: a Danish nationwide case-control study","volume":"7","author":"Tuyet Kristensen","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.05.005_bib0048","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00277-020-03950-6","article-title":"The impact of statins on the intensity of phlebotomies in polycythemia vera","volume":"99","author":"Kre\u010dak","year":"2020","journal-title":"Ann Hematol"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.05.005_bib0049","doi-asserted-by":"crossref","first-page":"18889","DOI":"10.1002\/cam4.6528","article-title":"Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia","volume":"12","author":"Podoltsev","year":"2023","journal-title":"Cancer Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.05.005_bib0050","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/bloodadvances.2025018724","article-title":"Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms","volume":"10","author":"Leiva","year":"2026","journal-title":"Blood Adv"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.05.005_bib0051","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0002-9343(81)90212-6","article-title":"Characterization of hypocholesterolemia in myeloproliferative disease. Relation to disease manifestations and activity","volume":"71","author":"Gilbert","year":"1981","journal-title":"Am J Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.005_bib0052","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3960\/jslrt.52.85","article-title":"Hypocholesterolemia in patients with polycythemia vera","volume":"52","author":"Fujita","year":"2012","journal-title":"J Clin Exp Hematop"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.05.005_bib0053","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s12185-022-03321-z","article-title":"Prognostic impacts of serum levels of C-reactive protein, albumin, and total cholesterol in patients with myelodysplastic syndromes","volume":"116","author":"Yanagisawa","year":"2022","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.05.005_bib0054","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-020-00963-6","article-title":"Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals","volume":"13","author":"Pedersen","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.05.005_bib0055","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/bloodadvances.2025019152","article-title":"Low serum cholesterol is a biomarker of advanced disease and poor outcomes in myeloproliferative neoplasms","volume":"10","author":"Leiva","year":"2026","journal-title":"Blood Adv"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.05.005_bib0056","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.05.005_bib0057","doi-asserted-by":"crossref","first-page":"6467","DOI":"10.21037\/apm-21-1022","article-title":"The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Wang","year":"2021","journal-title":"Ann Palliat Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.05.005_bib0058","doi-asserted-by":"crossref","first-page":"844","DOI":"10.14740\/jocmr2760w","article-title":"Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys","volume":"8","author":"Sano","year":"2016","journal-title":"J Clin Med Res"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.05.005_bib0059","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.17086","article-title":"Sodium-glucose cotransporter 2 inhibitors, erythrocytosis, and thrombosis in adults with type 2 diabetes","volume":"8","author":"Lewis","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.05.005_bib0060","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12933-025-02805-6","article-title":"Prevalence and thrombotic risk of SGLT-2 inhibitor-associated erythrocytosis: a retrospective cohort study","volume":"24","author":"Lee","year":"2025","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.05.005_bib0061","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12933-025-02871-w","article-title":"Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort study","volume":"24","author":"Mohamed","year":"2025","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.05.005_bib0062","doi-asserted-by":"crossref","first-page":"E298","DOI":"10.1002\/ajh.27048","article-title":"Sodium-glucose co-transporter-2 inhibitor treatment in essential thrombocythemia: impact on hemoglobin\/hematocrit levels and outcomes among 11 consecutive patients","volume":"98","author":"Gangat","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2026.05.005_bib0063","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/blood-2023-179596","article-title":"Sodium-glucose Co-transporter-2 inhibitor use in the setting of myeloproliferative neoplasms: impact on hemoglobin\/hematocrit levels and thrombosis risk","volume":"142","author":"Gangat","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.005_bib0064","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4274\/tjh.galenos.2024.2024.0050","article-title":"Myeloproliferative neoplasms and sodium-glucose Co-transporter-2 inhibitors: a case series","volume":"41","author":"Pat\u0131r","year":"2024","journal-title":"Turk J Haematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.05.005_bib0065","first-page":"e212","volume":"82","author":"Writing Committee","year":"2025","journal-title":"Hypertension"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.05.005_bib0066","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1007\/s00277-023-05417-w","article-title":"Renin-angiotensin inhibitors reduce thrombotic complications in essential thrombocythemia and polycythemia vera patients with arterial hypertension","volume":"102","author":"Mulas","year":"2023","journal-title":"Ann Hematol"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.05.005_bib0067","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1182\/blood-2014-07-591610","article-title":"In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology","volume":"124","author":"Barbui","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.05.005_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.bvth.2025.100051","article-title":"Cardiovascular risk factors in myeloproliferative neoplasms: associations with survival and thrombotic outcomes","volume":"2","author":"How","year":"2025","journal-title":"Blood Vessel Thromb Hemost"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.05.005_bib0069","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-11-752600","article-title":"ACE inhibitors and cytoreductive therapy in polycythemia vera","volume":"129","author":"Barbui","year":"2017","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.05.005_bib0070","first-page":"4089","article-title":"Local bone marrow renin-angiotensin system in the genesis of leukemia and other malignancies","volume":"20","author":"Haznedaroglu","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.05.005_bib0071","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Gerds","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.005_bib0072","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jama.2024.20377","article-title":"Diagnosis and treatment of polycythemia vera: a review","volume":"333","author":"Tremblay","year":"2025","journal-title":"JAMA"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.05.005_bib0073","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/ajh.24851","article-title":"A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study","volume":"92","author":"Barbui","year":"2017","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.05.005_bib0074","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/bloodadvances.2019001158","article-title":"Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis","volume":"4","author":"Masciulli","year":"2020","journal-title":"Blood Adv"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.05.005_bib0075","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/cncr.34195","article-title":"Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance\/intolerance to hydroxyurea","volume":"128","author":"Alvarez-Larran","year":"2022","journal-title":"Cancer"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.05.005_bib0076","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/ejh.70113","article-title":"Polycythemia vera and essential thrombocythemia: a nationwide population-based study on treatment patterns, vascular complications and survival","volume":"116","author":"Larsson","year":"2026","journal-title":"Eur J Haematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.05.005_bib0077","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1038\/s41375-022-01673-3","article-title":"Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients","volume":"36","author":"Mora","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.05.005_bib0078","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70000","article-title":"Treatment of myeloproliferative neoplasms with Janus kinase inhibitors: a meta-analysis of cardiovascular safety","volume":"6","author":"Dunn","year":"2025","journal-title":"EJHaem"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.05.005_bib0079","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10428194.2026.2639642","article-title":"Ruxolitinib and heart failure outcomes among patients with myelofibrosis","volume":"67","author":"Leiva","year":"2026","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.05.005_bib0080","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-alpha vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632600048X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003719632600048X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:57:36Z","timestamp":1792126656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003719632600048X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S003719632600048X"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.05.005","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}